Peptides and Healing: What the Research Says

Across the published literature, "peptides and healing" is not one research question. It spans short amino-acid chains studied as wound dressings and scaffolds, as endogenous signalling molecules in tissue repair, as oral supplements in connective-tissue trials, and as injectables discussed in clinical review articles. These literatures sit at very different stages of maturity, and the majority of the published work was generated in cells and animals rather than in people. This page summarises what individual papers examined and what they reported, with the study model labelled every time.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any wound, injury, medical condition or treatment decision. Nothing here describes a protocol, and no paper below is presented as a recommendation.

Why the model label matters more than the compound name

A finding only means what the model it came from allows it to mean. Four broad tiers appear in this literature:

• In vitro — cells, bacteria or biochemical assays in a dish. Useful for mechanism, not for predicting clinical outcomes.
• In vivo (animal) — usually rodent wound, diabetic-wound or infected-wound models. Healing kinetics in rodents differ substantially from human wound biology.
• Human trials — randomised controlled trials in people, with pre-specified measured endpoints.
• Reviews and drug profiles — secondary sources that summarise or track a field; they generate no new data.

In the papers surveyed below, the materials-science and preclinical tier dominates. For example, a 2022 study reported wound healing-promoting activities of the phosvitin-derived peptide Pt5-1c in both in vitro and in vivo experiments (PMID 35183532), which is a laboratory and animal finding, not a clinical one.

Study-by-study overview

Peptide biomaterials: hydrogels, patches and matrices

The single largest cluster of peptide-and-healing research is not about injections at all. It is materials science: peptides used as building blocks for gels, patches and scaffolds placed onto a wound. Self-assembling peptides can form fibrous networks that hold water, carry drugs and present cell-binding motifs, which is why this work appears in biomaterials journals rather than clinical ones.

Diabetic and hard-to-close wounds

Diabetic wound models are a recurring test bed because impaired repair is easy to reproduce and hard to correct. A 2024 study described an engineered biomimetic nanovesicles-laden multifunctional hydrogel and reported enhanced targeted therapy of diabetic wounds in preclinical testing (PMID 39624053). Separately, a 2025 paper in Wound Repair and Regeneration reported that a bioinspired provisional matrix stimulated regenerative healing of diabetic wounds in a preclinical model (PMID 40899619). Both were laboratory-stage constructs rather than human trials, and neither was described as an approved product.

Infected wounds and antibacterial design

Several groups combined repair-oriented scaffolds with antibacterial function. A 2025 report described a food-derived tripeptide-copper self-healing hydrogel applied to infected wound healing (PMID 39902373). A 2024 study described a pH-responsive co-assembled peptide hydrogel and reported inhibition of drug-resistant bacterial infection alongside promotion of wound healing in preclinical work (PMID 38576193). A 2023 paper reported a poly(aspartic acid)-based self-healing hydrogel with precise antibacterial ability used for rapid infected-wound repairing in preclinical experiments (PMID 36347184). The shared theme is dual-function design: the material is meant to manage bacterial burden while also serving as a repair scaffold.

Fabricated patches

Fabrication methods matter as much as chemistry. A 2022 study described 3D-bioprinted peptide coupling patches developed for wound healing, a preclinical engineering approach in which peptide motifs were coupled into a printed construct (PMID 34977527).

Scar formation and inflammation

Not every repair endpoint is closure speed. A 2020 study reported that resveratrol-loaded peptide hydrogels inhibited scar formation in wound healing through suppression of inflammation in preclinical testing (PMID 32440361). Here the peptide acted mainly as a delivery vehicle, which is a common design in this literature and an important distinction: the measured effect was attributed to the loaded compound and the inflammatory pathway, not to a peptide acting alone.

Human trial evidence in this set

Only one paper in this citation set generated human data. A 16-week randomised controlled trial reported that collagen peptide supplementation enhanced muscle-tendon stiffness and explosive strength (PMID 40623147). The endpoints there were connective-tissue mechanical properties and performance measures in participants, not wound closure. That distinction matters when the word "healing" is used loosely: tendon and muscle-tendon adaptation, skin wound closure and scar quality are separate outcomes measured with separate tools, and results from one do not transfer to another. The study was a supplementation trial, and its findings describe what researchers measured over that 16-week period in that population.

Injectable peptides in orthopaedic and sports medicine

Interest in injectable peptides for musculoskeletal complaints has outpaced the controlled evidence. A 2026 article in The American Journal of Sports Medicine was published as a primer on injectable peptide therapy written for orthopaedic and sports medicine physicians (PMID 41476424). As a review-format primer, it summarised and contextualised an existing field for clinicians rather than reporting new trial outcomes, and it belongs in the "secondary source" tier described above. Readers interested in what clinical literature exists for injectable peptides can consult that record directly.

Endogenous peptides and investigational peptide drugs

A separate strand studies peptides the body already makes. A 2025 mechanistic study reported that acupuncture accelerated wound healing via CGRP-RAMP1-TSP1-mediated macrophage M2 polarization (PMID 41250153), placing a neuropeptide signalling axis and macrophage phenotype switching at the centre of the repair mechanism rather than an administered peptide product. That framing is common in repair biology: the peptide is a signal within a pathway, and the intervention modulates the pathway.

Investigational peptide drugs form another strand. A 2001 drug profile in IDrugs covered relaxin, a naturally occurring peptide hormone, and its development status under Connetics and Celltech (PMID 16032483). Drug profiles of this kind document a development pipeline at a point in time; they are not trial reports, and a profile's existence says nothing about eventual approval or outcome.

Adverse Events: What Studies Report

The verified papers surveyed here were overwhelmingly efficacy- and mechanism-oriented, and their stated endpoints were repair-related rather than systematic safety surveillance. Preclinical biomaterials reports such as the tripeptide-copper hydrogel work (PMID 39902373) and the pH-responsive peptide hydrogel study (PMID 38576193) were framed around material behaviour, antibacterial activity and wound outcomes in laboratory models, which is a different evidentiary purpose from human tolerability data. The clinical primer on injectable peptide therapy (PMID 41476424) was written for physicians and is the appropriate record to consult for clinical framing. No safety conclusions should be drawn from an animal or in vitro repair study, and none are drawn here.

Limitations and open questions

• Model ceiling. Rodent and cell-culture wound outcomes, including those in the Pt5-1c study (PMID 35183532), do not establish human effects.
• Vehicle versus payload. Where a peptide gel carried another molecule, as in the resveratrol-loaded hydrogel work (PMID 32440361), the reported effect cannot be assigned to the peptide alone.
• Endpoint mismatch. Tendon stiffness and strength measures in a 16-week human trial (PMID 40623147) are not wound-closure endpoints.
• Topical versus systemic. Patches and matrices applied to a wound bed, such as the bioprinted peptide patches (PMID 34977527), have no bearing on systemically administered compounds.
• Publication stage. A development profile like the relaxin record (PMID 16032483) reflects a snapshot, not an outcome.

Taken together, the published record on peptides and healing is broad, active and largely preclinical. Readers evaluating any specific claim can check which tier it came from, what was actually measured, and whether the endpoint matches the question being asked.

References

• Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (The American Journal of Sports Medicine, 2026)
• Engineered biomimetic nanovesicles-laden multifunctional hydrogel enhances targeted therapy of diabetic wound (Materials Today Bio, 2024)
• Food-Derived Tripeptide-Copper Self-Healing Hydrogel for Infected Wound Healing (Biomaterials Research, 2025)
• pH-Responsive Co-Assembled Peptide Hydrogel to Inhibit Drug-Resistant Bacterial Infection and Promote Wound Healing (ACS Applied Materials & Interfaces, 2024)
• Collagen Peptide Supplementation Enhances Muscle-Tendon Stiffness and Explosive Strength: A 16-wk Randomized Controlled Trial (Medicine and Science in Sports and Exercise, 2025)
• Resveratrol-loaded peptide-hydrogels inhibit scar formation in wound healing through suppressing inflammation (Regenerative Biomaterials, 2020)
• Poly(aspartic acid)-based self-healing hydrogel with precise antibacterial ability for rapid infected-wound repairing (Colloids and Surfaces B: Biointerfaces, 2023)
• 3D-bioprinted peptide coupling patches for wound healing (Materials Today Bio, 2022)
• Acupuncture accelerates wound healing via CGRP-RAMP1-TSP1-mediated macrophage M2 polarization (Chinese Medicine, 2025)
• Relaxin (Connetics/Celltech) (IDrugs: The Investigational Drugs Journal, 2001)
• Bioinspired Provisional Matrix Stimulates Regenerative Healing of Diabetic Wounds (Wound Repair and Regeneration, 2025)
• In vitro and in vivo wound healing-promoting activities of phosvitin-derived peptide Pt5-1c (European Journal of Pharmacology, 2022)